Role of Lactobacillus plantarum 299v versus Placebo in symptomatic improvement of irritable bowel syndrome patients
- PMID: 35320214
- DOI: 10.47391/JPMA.0758
Role of Lactobacillus plantarum 299v versus Placebo in symptomatic improvement of irritable bowel syndrome patients
Abstract
Objectives: To find the efficacy of lactobacillus plantarum 299v compared to placebo in symptomatic improvement of irritable bowel syndrome patients.
Methods: The randomised control trial was conducted at the Lady Reading Hospital, Peshawar, Pakistan, from July 20, 2014, to January 20, 2015, and comprised irritable bowel syndrome patients who were randomised into intervention group A treated with lactobacillus plantarum 299v and control group B treated with placebo. Symptoms, like abdominal pain, bloating and complete rectal emptying, were noted and compared between the groups. Data was analysed using SPSS 19.
Results: Of the 190 patients assessed, 120(63%) were included; 60(50%) in each of the two groups. After loss to follow-up, the study was completed by 55(91.7%) in group A and 53(88.3%) in group B. The mean age in group A was 37.53±9.02 and it was 34.40±11.23 in group B (p=0.652). The male-to-female ratio and irritable bowel syndrome type in both the groups was not significantly different (p>0.055). There was no significant difference in terms of relieving abdominal pain, bloating and rectal emptying between the groups (p>0.05).
Conclusions: No significant efficacy was established in favour of treating in irritable bowel syndrome with lactobacillus plantarum 299v.
Trials registration: IRCT20200504047303N1.
Keywords: IBS, Lactobacillus plantarum 299v, Placebo..
Similar articles
-
Clinical trial: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome.World J Gastroenterol. 2012 Aug 14;18(30):4012-8. doi: 10.3748/wjg.v18.i30.4012. World J Gastroenterol. 2012. PMID: 22912552 Free PMC article. Clinical Trial.
-
Randomized clinical trial: effect of Lactobacillus plantarum 299 v on symptoms of irritable bowel syndrome.Nutrition. 2014 Oct;30(10):1151-7. doi: 10.1016/j.nut.2014.02.010. Epub 2014 Feb 27. Nutrition. 2014. PMID: 25194614 Clinical Trial.
-
Lactobacillus acidophilus versus placebo in the symptomatic treatment of irritable bowel syndrome: the LAPIBSS randomized trial.Cell Mol Biol (Noisy-le-grand). 2017 Sep 30;63(9):122-131. doi: 10.14715/cmb/2017.63.9.21. Cell Mol Biol (Noisy-le-grand). 2017. PMID: 28980935 Clinical Trial.
-
Efficacy of Probiotics in Irritable Bowel Syndrome: Systematic Review and Meta-analysis.Gastroenterology. 2023 Nov;165(5):1206-1218. doi: 10.1053/j.gastro.2023.07.018. Epub 2023 Aug 3. Gastroenterology. 2023. PMID: 37541528
-
Evaluation of the efficacy of probiotics as treatment in irritable bowel syndrome.Endocrinol Diabetes Nutr (Engl Ed). 2024 Jan;71(1):19-30. doi: 10.1016/j.endien.2024.01.003. Epub 2024 Feb 7. Endocrinol Diabetes Nutr (Engl Ed). 2024. PMID: 38331656 Review.
Cited by
-
Nutrition, Physical Activity and Supplementation in Irritable Bowel Syndrome.Nutrients. 2023 Aug 21;15(16):3662. doi: 10.3390/nu15163662. Nutrients. 2023. PMID: 37630852 Free PMC article. Review.
-
The Role of Gastrointestinal Microbiota in Functional Dyspepsia: A Review.Front Physiol. 2022 Jun 8;13:910568. doi: 10.3389/fphys.2022.910568. eCollection 2022. Front Physiol. 2022. PMID: 35755434 Free PMC article. Review.
-
Strain-Specific Therapeutic Potential of Lactiplantibacillus plantarum: A Systematic Scoping Review.Nutrients. 2025 Mar 27;17(7):1165. doi: 10.3390/nu17071165. Nutrients. 2025. PMID: 40218922 Free PMC article.